Asia Cervical Cancer Test (Screening) Market will reach US$ 4.5 Billion by 2028, according to Renub Research. Among females in Asia, cervical cancer holds the position of the fourth leading cause of cancer. Effectively managing and detecting cervical cancer early on is crucial in its fight, as it is recognized as one of the most preventable and treatable forms of cancer. This disease underscores the problem of inequity since it is preventable. As awareness about the importance of early detection and prevention increases, more women are seeking regular screenings. Cervical cancer is primarily caused by persistent infection with high-risk types of the human papillomavirus (HPV). Other risk factors include smoking, weakened immune system, long-term use of oral contraceptives, and a family history of cervical cancer.

Governments and healthcare organizations in the Asia Pacific are also implementing initiatives to promote cervical cancer screening programs, including education campaigns and improved access to screening facilities. These efforts aim to reduce the incidence and mortality rates associated with cervical cancer in the region. With advanced technologies and increased emphasis on women’s health, the Asia Pacific is experiencing positive trends in cervical cancer screening, leading to improved outcomes and lives saved.


Asia cervical cancer screening industry is projected to grow at a compound annual growth rate (CAGR) of 3.79% between 2022 and 2028

Cervical cancer offers a significant opportunity for prevention, screening, early detection, and treatment in Asia Pacific. Taking steps to implement interventions throughout the prevention and control continuum can effectively reduce the burden of this disease and empower women to live healthy and productive lives. Increased awareness about the importance of early detection, coupled with healthcare initiatives and government efforts, has contributed to the rising trend. Screening programs and improved accessibility to screening facilities are driving the uptake of cervical cancer screening in the region. These advancements aim to reduce the burden of the disease and improve women’s health outcomes across Asia.

However, despite the clear benefits and strong rationale for investing in strategies for cervical cancer prevention and control, there is still a lack of sufficient investment, particularly in preventive measures. It is crucial to prioritize and allocate resources towards preventive measures to effectively address cervical cancer and its impact on women’s health. The size of the Asia cervical cancer test (screening) market was US$ 3.60 Billion in 2022.


Japan cervical cancer test (screening) market is rapidly growing, making it one of the fastest-growing segments in the country’s healthcare industry

By Country, Asia cervical cancer test (screening) market is breakup into Japan, Korea, Singapore, Malaysia, India, China, Thailand and Indonesia. With a focus on preventive healthcare, Japan has implemented robust screening programs to detect cervical cancer at early stages. The market is supported by government initiatives, such as providing subsidized screenings and raising awareness among women. Advanced technologies, such as liquid-based cytology and human papillomavirus (HPV) testing, are widely utilized in Japan’s screening practices. The market’s growth is driven by the increasing emphasis on women’s health, proactive healthcare policies, and the commitment to reduce the burden of cervical cancer in the country.


Japan dominates the Pap smear industry with the highest market share in the country

Pap Smear Market, Asia cervical cancer test (screening) market is divided into Japan, Korea, Singapore, Malaysia, India, China, Thailand and Indonesia. The pap smear market in Japan holds significant importance within the healthcare landscape. Pap smear testing, also known as cervical cytology, is widely utilized for the early detection of cervical cancer and precancerous abnormalities. Japan places a strong emphasis on preventive healthcare, leading to a growing demand for pap smear services. The market is supported by well-established screening programs, widespread awareness campaigns, and advanced laboratory infrastructure. With ongoing technological advancements and increasing awareness among women, the Japan pap smear market is expected to exhibit steady growth in the coming years, playing a crucial role in cervical cancer prevention and early intervention.


Japan HPV DNA segment is experiencing remarkable growth, positioning it as the fastest-growing market in this field

The HPV DNA market in the Asia cervical cancer test (screening) market is segmented into several key countries, including Japan, Korea, Singapore, Malaysia, India, China, and Indonesia. These countries play a significant role in the region’s cervical cancer screening efforts, with dedicated healthcare initiatives and advanced testing technologies. Japan stands out as the fastest-growing market in the HPV DNA Industry. With its advanced healthcare system and proactive initiatives, the country has witnessed a significant rise in the adoption of HPV DNA testing for cervical cancer screening.

Japan’s strong emphasis on preventive healthcare and early detection, coupled with extensive awareness campaigns, has fueled the growth of the HPV DNA market. The increasing demand for accurate and reliable screening methods, along with advancements in testing technologies, has further propelled Japan’s position as a leader in the HPV DNA market, contributing to improved cervical cancer prevention and management.


China dominates the VIA industry with the highest market share in the country

VIA Market, Asia cervical cancer test (screening) market is sub segmented into India, China, Thailand and Indonesia. China holds the highest market share in the Visual Inspection with Acetic Acid (VIA) industry. VIA is a cost-effective and accessible screening method for cervical cancer. With its vast population and proactive healthcare initiatives, China has implemented widespread VIA screening programs. The country’s commitment to women’s health, combined with increased awareness and accessibility, has propelled China to the forefront of the VIA industry, addressing the significant burden of cervical cancer and improving early detection rates.

India is poised to capture a significant market share in the Visual Inspection with Acetic Acid (VIA) industry. The country’s large population and focus on improving women’s healthcare make it an ideal market for VIA screening. With increasing awareness, government initiatives, and efforts to enhance accessibility to healthcare services, India is well-positioned to address the burden of cervical cancer through VIA screenings. India’s potential to capture a substantial market share highlights its commitment to women’s health and early detection of cervical cancer.


Key Company

AstraZeneca, Hologic Corporation, Becton, Siemens AG, Roche Diagnostics, Quest Diagnostics, and Cardinal Health are prominent players in the Asia cervical cancer test (screening) industry. These companies are at the forefront of developing and providing advanced solutions for cervical cancer screening and diagnosis. With their expertise and innovative technologies, they play a vital role in promoting early detection and prevention of cervical cancer across the region. Their contributions in raising awareness, improving testing accuracy, and enhancing access to screening services are instrumental in reducing the burden of cervical cancer and improving women’s health outcomes in Asia.


Renub Research report titled “Asia Cervical Cancer Test (Screening) Market by Type (Pap smear Market, HPV DNA Market, VIA Market), by Countries (Japan, Korea, Singapore, Malaysia, India, China, and Indonesia), Company (AstraZeneca, Hologic Corporation, Becton, Siemens AG, Roche Diagnostics, Quest Diagnostics, and Cardinal Health)? provide complete detail on Asia Cervical Cancer Test (Screening) Industry.


Type – Market has been covered from 3 viewpoints:

1. Pap smear Market
2. HPV DNA Market
3. VIA (visual inspection with acetic acid) Market


Pap smear Market – 8 Country have been covered

1. Japan
2. Korea
3. Singapore
4. Malaysia
5. India
6. China
7. Thailand
8. Indonesia


2. HPV DNA Market – 7 Country have been covered

1. Japan
2. Korea
3. Singapore
4. Malaysia
5. India
6. China
7. Indonesia


3. VIA (visual inspection with acetic acid) Market – 4 Country have been covered

1. India
2. China
3. Thailand
4. Indonesia


Companies have been covered from 3 viewpoints


    • Overview
    • Recent Development
    • Sales




Company Covered

1. AstraZeneca
2. Hologic Corporation
3. Becton
4. Siemens AG
5. Roche Diagnostics
6. Quest Diagnostics
7. Cardinal Health